Ivermectin Prophylaxis Used for COVID-19 Studies

A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching

Analyzed data from a prospective, observational study of the citywide COVID-19 prevention with ivermectin program, which was conducted between July 2020 and December 2020 in Itajaí, Brazil.

Background: Ivermectin has demonstrated different mechanisms of action that potentially protect from both coronavirus disease 2019 (COVID-19) infection and COVID-19-related comorbidities. Based on the studies suggesting efficacy in prophylaxis combined with the known safety profile of ivermectin, a citywide prevention program using ivermectin for COVID-19 was implemented in Itajaí, a southern city in Brazil in the state of Santa Catarina. The objective of this study was to evaluate the impact of regular ivermectin use on subsequent COVID-19 infection and mortality rates.

Ivermectin has been demonstrated to have not only extensive anti-parasitic actions [1,2], but also anti-viral, anti-bacterial, and anti-protozoan properties. Ivermectin has been long proposed for use as a repurposed antiviral agent [3-6]. Indeed, antiviral effects of ivermectin have been reported against both RNA and DNA types of viruses, including HIV-1, yellow fever, Japanese encephalitis, tick-borne encephalitis, West Nile, Zika, dengue fever, chikungunya, Venezuelan equine encephalitis, and the pseudorabies virus [3,5,7,8], as well as functioning in regulation of proteins involved in antiviral responses [8].